These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15503024)

  • 1. Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
    Woo MH; Peterson JK; Billups C; Liang H; Bjornsti MA; Houghton PJ
    Cancer Chemother Pharmacol; 2005 May; 55(5):411-9. PubMed ID: 15503024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
    Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
    Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
    Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ
    Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
    Thompson J; Zamboni WC; Cheshire PJ; Lutz L; Luo X; Li Y; Houghton JA; Stewart CF; Houghton PJ
    Clin Cancer Res; 1997 Mar; 3(3):423-31. PubMed ID: 9815701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
    Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
    Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
    Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of antitumor activities in tumor xenograft treatment.
    Liang H
    Contemp Clin Trials; 2007 Feb; 28(2):115-9. PubMed ID: 16814615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
    Britten CD; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
    Cancer Res; 1999 Mar; 59(5):1049-53. PubMed ID: 10070962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
    Houghton PJ; Stewart CF; Cheshire PJ; Richmond LB; Kirstein MN; Poquette CA; Tan M; Friedman HS; Brent TP
    Clin Cancer Res; 2000 Oct; 6(10):4110-8. PubMed ID: 11051264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
    Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
    Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.
    Furman WL; Stewart CF; Poquette CA; Pratt CB; Santana VM; Zamboni WC; Bowman LC; Ma MK; Hoffer FA; Meyer WH; Pappo AS; Walter AW; Houghton PJ
    J Clin Oncol; 1999 Jun; 17(6):1815-24. PubMed ID: 10561220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of oral irinotecan against neuroblastoma xenografts.
    Thompson J; Zamboni WC; Cheshire PJ; Richmond L; Luo X; Houghton JA; Stewart CF; Houghton PJ
    Anticancer Drugs; 1997 Apr; 8(4):313-22. PubMed ID: 9180383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
    Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
    Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
    Pappo AS; Lyden E; Breitfeld P; Donaldson SS; Wiener E; Parham D; Crews KR; Houghton P; Meyer WH;
    J Clin Oncol; 2007 Feb; 25(4):362-9. PubMed ID: 17264331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
    Van Laar ES; Weitman S; MacDonald JR; Waters SJ
    Prostate; 2004 Apr; 59(1):22-32. PubMed ID: 14991863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo.
    Van Laar ES; Roth S; Weitman S; MacDonald JR; Waters SJ
    Anticancer Res; 2004; 24(1):59-65. PubMed ID: 15015576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
    Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
    Rodriguez-Galindo C; Crews KR; Stewart CF; Furman W; Panetta JC; Daw NC; Cain A; Tan M; Houghton PH; Santana VM
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):15-24. PubMed ID: 16001174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
    Wagner LM; McAllister N; Goldsby RE; Rausen AR; McNall-Knapp RY; McCarville MB; Albritton K
    Pediatr Blood Cancer; 2007 Feb; 48(2):132-9. PubMed ID: 16317751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
    Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.